Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Smallcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences submitted audited results for Q4 and FY25. Consolidated revenue jumped 44% YoY to Rs 2,893.64 Cr, while standalone revenue grew 14% to Rs 1,697.75 Cr. However, standalone net profit fell sharply to Rs 77.39 Cr from Rs 299.72 Cr, dragged by much higher finance costs (Rs 220 Cr vs Rs 57 Cr), higher depreciation (Rs 182 Cr vs Rs 102 Cr) from acquisitions, and the expiry of Section 80IE tax benefits. Standalone operating margin compressed to 20% from 26% YoY. The auditor (Deloitte Haskins & Sells LLP) issued an unmodified opinion. The board also appointed a new secretarial auditor for five years and fixed May 23, 2025 as the record date for NCD interest payments.
Strong top-line growth is offset by a steep fall in standalone profit and meaningful margin compression, which may pressure the stock in the near term. Investors should track whether margin recovery follows the recent Biocon-branded formulations acquisition and the internal restructuring (sale of Eris Oaknet and Aprica investments to Eris Therapeutics for Rs 872 Cr).